A Randomized Control Trial of Hinex Jelly on the Changes in Muscle Quality and Quantity

Sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05917353
Collaborator
(none)
100
1
2
34.5
2.9

Study Details

Study Description

Brief Summary

Taiwan is about to enter a super-aged society in 2025. The health problems of the elderly are getting more and more attention. Among these geriatric issues, sarcopenia is an important issue. Sarcopenia is the culprit of disability in old age. It is characterized by persistent and general loss of skeletal muscle mass and function throughout the body, which may lead to disability, decreased quality of life, and even inability to take care of yourself and an increased risk of death. Human skeletal muscle decreases with age. After the age of 40, muscle mass will be lost at a rate of 8% per decade; after the age of 70, it will be lost at a faster rate of 15% per decade in average. Although all elderly will lose muscle mass due to aging, the degree and speed of loss vary from person to person. In addition to aging, it may also be caused by chronic diseases.

Exercise intervention and nutritional intervention are the first choices for sarcopenia intervention. Regarding nutritional requirements, the elderly need at least 15 grams of essential amino acids per day for muscle building. Among them, leucine is the most important, which can increase protein production and reduce decomposition. Foods rich in leucine include soybeans, fish or beef. However, elderly people may not be able to get enough protein from their daily diet smoothly, often because of dysphagia, such as dental problems or chewing and swallowing problems. Therefore, oral nutritional supplements are relatively important for the improvement of muscle mass. Nutritional Supplement Hinex Jelly has 303 calories per serving, contains up to 15g of high-quality protein and a high amount of branched-chain amino acids, which is beneficial for muscle synthesis and tissue repair, plus a variety of minerals, vitamins, water-soluble dietary fiber, hydrolyzed collagen and other ingredients can strengthen nutritional supplements, maintain good health.

In summary, this study intends to explore the effect of Hinex Jelly nutritional supplemental intervention on muscle mass quality and quantity changes by means of randomized intervention and controlled trials.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Hinex Jelly
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
A Randomized Control Trial of Hinex Jelly on the Changes in Muscle Quality and Quantity
Actual Study Start Date :
Aug 15, 2022
Anticipated Primary Completion Date :
Jun 30, 2025
Anticipated Study Completion Date :
Jun 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Hinex Jelly Nutritional Supplement Intervention Group

Week 0th, Week 4th (14 days before and after), Week 8th (14 days before and after), Week 12th (14 days before and after) and Weeks 24th (14 days before and after), diet and exercise health education was given, with daily intervention of Hinex Jelly nutritional supplements 1 serving per day during 0th to 8th Week;

Dietary Supplement: Hinex Jelly
Name: Hinex Jelly Dosage form: Semi-solid jelly/ A-114001297-00000-2 Dose(s): 300g/pack (per serving) Dosing schedule: one pack (serving) per day Mechanism of action: Nutritional supplement semi-solid food (content 61-91g/100g, protein 4.0-6.0/100g, saturated fatty acid 0.72-1.08g/100g, carbohydrate 12.56-18.84g/100g, dietary fiber 1.0-1.4g/100g), It is used as a nutritional supplement food.

No Intervention: Routine care group

Week 0th, Week 4th (14 days before and after), Week 8th (14 days before and after), Week 12th (14 days before and after) and Week 24th (14 days before and after), the subjects were given regular dietary and exercise health education.

Outcome Measures

Primary Outcome Measures

  1. Change from Baseline Appendicular skeletal muscle mass index at 8 weeks [8 weeks after the first session]

    Appendicular skeletal muscle mass index assessed using the Inbody S10

  2. Change from Baseline handgrip strength at 8 weeks [8 weeks after the first session]

    assessed with a Jamar handheld dynamometer in kilograms

  3. Change from Baseline performance on the 5-repetition sit-to-stand test at 8 weeks [8 weeks after the first session]

    assessed in seconds

  4. Change from Baseline performance on 6-metre walk test at 8 weeks [8 weeks after the first session]

    assessed in seconds

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adults over the age of 50 (include 50 years old).

  • Can cooperate with the study.

  • No surgical intervention within 3 months.

Exclusion Criteria:
  • Those who have obvious difficulty in movement (such as amputation) and cannot cooperate with the study.

  • Those who are equipped with pacemakers or internal electronic medical devices.

  • Pregnant women.

  • Use of drugs or interventional therapy that may affect changes in body weight or muscle mass (such as other oral nutritional supplements, medicine, weight reduction medicine, bariatric gastric endoscopy therapy, bariatric surgery, acupuncture, acupuncture, electrical stimulation, etc.).

  • Allergic to dairy or soy products.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kaohsiung Medical University Hospital Kaohsiung Taiwan 807

Sponsors and Collaborators

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kaohsiung Medical University Chung-Ho Memorial Hospital
ClinicalTrials.gov Identifier:
NCT05917353
Other Study ID Numbers:
  • KMUHIRB-F(I)-20220124
First Posted:
Jun 23, 2023
Last Update Posted:
Jun 23, 2023
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 23, 2023